Cargando…

Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients

Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Bernice Ling Zhi, Tan, Nicole, de Alwis, Ruklanthi, Kunasegaran, Kamini, Chen, Zhiwei, Poon, Michelle, Chan, Esther, Low, Jenny G. H., Yeoh, Allen Eng Juh, Bertoletti, Antonio, Le Bert, Nina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Letters to Blood
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281508/ https://www.ncbi.nlm.nih.gov/pubmed/35472242 http://dx.doi.org/10.1182/blood.2022016166

Ejemplares similares

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
por: Enßle, Julius C., et al.
Publicado: (2022)

BNT162b2 mRNA Vaccine–Induced Immune Response in Oral Fluids and Serum
por: Seneviratne, Chaminda Jayampath, et al.
Publicado: (2022)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

Buckling up against COVID-19 after CAR T-cell therapy
por: Auletta, Jeffery J.
Publicado: (2022)

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
por: Frigault, Matthew J., et al.
Publicado: (2020)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Adverse effects following anti–COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes
por: Syenina, Ayesa, et al.
Publicado: (2022)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

This CAR won’t start: predicting nonresponse in ALL
por: Webster, Jonathan A., et al.
Publicado: (2023)

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023)

Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
por: de Alwis, Ruklanthi, et al.
Publicado: (2020)

BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: a cohort study
por: Yung, Chee Fu, et al.
Publicado: (2023)

On a collision course: SARS-CoV-2 variants and CAR T cells
por: Auletta, Jeffery J.
Publicado: (2023)

Ensuring HLA‐matched platelet support requires an ethnic diverse donor population
por: Kreuger, Aukje L., et al.
Publicado: (2020)

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
por: Khoo, Nicholas Kim Huat, et al.
Publicado: (2022)

Isolated systolic hypertension of the young and its association with central blood pressure in a large multi-ethnic population. The HELIUS study
por: Eeftinck Schattenkerk, Daan W, et al.
Publicado: (2018)

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
por: Loo, Sun, et al.
Publicado: (2022)

Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione
por: North, Anne K., et al.
Publicado: (2020)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients
por: Liebers, Nora, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Systematic review protocol: an assessment of the post-approval challenges of autologous CAR-T therapy delivery
por: Lam, Ching, et al.
Publicado: (2019)

White Matter Tract Changes Associated with Clinical Improvement in an Open‐Label Trial Assessing Autologous Umbilical Cord Blood for Treatment of Young Children with Autism
por: Carpenter, Kimberly L. H., et al.
Publicado: (2019)

Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron
por: Wei, Yuchen, et al.
Publicado: (2023)

Evaluation of amotosalen and UVA pathogen‐reduced apheresis platelets after 7‐day storage
por: Cancelas, Jose A., et al.
Publicado: (2022)

Performance characteristics of a novel blood bag in-line closure device and subsequent product quality assessment
por: Serrano, Katherine, et al.
Publicado: (2010)

Failure of self-disclosure of deferrable risk behaviors associated with transfusion-transmissible infections in blood donors
por: Wong, Horas Tze Hoo, et al.
Publicado: (2015)

Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone
por: Tedder, Richard S., et al.
Publicado: (2018)

Estimation of the number of blood donors during the COVID‐19 incubation period across China and analysis of prevention and control measures for blood transfusion transmission
por: Yuan, Zhaohu, et al.
Publicado: (2020)

Deferral rate variability in blood donor eligibility assessment
por: de Kort, Wim, et al.
Publicado: (2018)

First results of a ferritin‐based blood donor deferral policy in the Netherlands
por: Vinkenoog, Marieke, et al.
Publicado: (2020)

Determinants of blood donation willingness in the European Union: a cross‐country perspective on perceived transfusion safety, concerns, and incentives
por: Huis in ‘t Veld, Elisabeth M.J., et al.
Publicado: (2019)

Prediction paradigm involving time series applied to total blood issues data from England
por: Nandi, Anita K., et al.
Publicado: (2020)

Do deferred donors continue their donations? A large‐scale register study on whole blood donor return in the Netherlands
por: Spekman, Marloes L.C., et al.
Publicado: (2019)

Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study
por: Zhao, Jingcheng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_assba90t63jg9sqqi7pb4srd5i